Cytek Biosciences (CTKB) Asset Writedowns and Impairment (2020 - 2026)
Cytek Biosciences (CTKB) posted Asset Writedowns and Impairment of $193000.0 for Q1 2026, up 457.41% on a QoQ basis from -$54000.0 in Q4 2025, and down 38.54% year-over-year from $314000.0 in Q1 2025.
Cytek Biosciences (CTKB) Asset Writedowns and Impairment (2020 - 2026) Analysis & Trends
Cytek Biosciences' Asset Writedowns and Impairment history runs 7 years deep, the most recent figure standing at $193000.0 for Q1 2026.
- Quarterly Asset Writedowns and Impairment fell 38.54% year-over-year to $193000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $292000.0 (down 72.14% YoY) and the FY2025 annual result came in at $413000.0, down 74.91% from the prior year.
- Asset Writedowns and Impairment was $193000.0 for Q1 2026 at Cytek Biosciences, up from -$54000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $1.7 million in Q4 2024 and bottomed at -$985000.0 in Q2 2024.
- A 5-year average of $298400.0 and a median of $213000.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment soared 467.24% — and 2024, when it plunged 7135.71%.
- Cytek Biosciences' Asset Writedowns and Impairment stood at $294000.0 in 2022, then soared by 127.89% to $670000.0 in 2023, then jumped by 156.57% to $1.7 million in 2024, then plunged by 103.14% to -$54000.0 in 2025, then soared by 457.41% to $193000.0 in 2026.
- Business Quant data shows CTKB's Asset Writedowns and Impairment at $193000.0 in Q1 2026, -$54000.0 in Q4 2025, and $415000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Cytek Biosciences | 586.89 Mn | 521.19 Mn | 21.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 193,000.00 |
| Mar 31, 2026 | 193,000.00 |
| Dec 31, 2025 | -54,000.00 |
| Dec 31, 2025 | -54,000.00 |
| Sep 30, 2025 | 415,000.00 |
| Sep 30, 2025 | 415,000.00 |
| Jun 30, 2025 | -262,000.00 |
| Jun 30, 2025 | -262,000.00 |
| Mar 31, 2025 | 314,000.00 |
| Mar 31, 2025 | 314,000.00 |
| Dec 31, 2024 | 1.72 Mn |
| Dec 31, 2024 | 1.72 Mn |
| Jun 30, 2024 | -985,000.00 |
| Jun 30, 2024 | -985,000.00 |
| Mar 31, 2024 | 912,000.00 |
| Mar 31, 2024 | 912,000.00 |
| Dec 31, 2023 | 670,000.00 |
| Dec 31, 2023 | 670,000.00 |
| Sep 30, 2023 | 784,000.00 |
| Sep 30, 2023 | 784,000.00 |